174 related articles for article (PubMed ID: 36768392)
1. TZD-Based Hybrid Molecules Act as Dual Anti-
Dzitko K; Kaproń B; Paneth A; Bekier A; Plech T; Paneth P; Trotsko N
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768392
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of
Węglińska L; Bekier A; Trotsko N; Kaproń B; Plech T; Dzitko K; Paneth A
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2621-2634. PubMed ID: 36165032
[TBL] [Abstract][Full Text] [Related]
3. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sulfadiazine and pyrimetamine for treatment of experimental toxoplasmosis with strains obtained from human cases of congenital disease in Brazil.
Silva LA; Fernandes MD; Machado AS; Reis-Cunha JL; Bartholomeu DC; Almeida Vitor RW
Exp Parasitol; 2019 Jul; 202():7-14. PubMed ID: 31077733
[TBL] [Abstract][Full Text] [Related]
5. Combined In Silico and In Vitro Analyses to Assess the Anticancer Potential of Thiazolidinedione-Thiosemicarbazone Hybrid Molecules.
Paneth A; Kaproń B; Plech T; Paduch R; Trotsko N; Paneth P
Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139350
[TBL] [Abstract][Full Text] [Related]
6. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain.
Liu S; Wu M; Hua Q; Lu D; Tian Y; Yu H; Cheng L; Chen Y; Cao J; Hu X; Tan F
Parasit Vectors; 2020 May; 13(1):242. PubMed ID: 32393321
[TBL] [Abstract][Full Text] [Related]
7. Treatments of
Ifijen IH; Atoe B; Ekun RO; Ighodaro A; Odiachi IJ
Bionanoscience; 2023; 13(1):249-277. PubMed ID: 36687337
[No Abstract] [Full Text] [Related]
8. Drug Resistance in
Montazeri M; Mehrzadi S; Sharif M; Sarvi S; Tanzifi A; Aghayan SA; Daryani A
Front Microbiol; 2018; 9():2587. PubMed ID: 30420849
[No Abstract] [Full Text] [Related]
9. A new iron(III) complex-containing sulfadiazine inhibits the proliferation and induces cystogenesis of Toxoplasma gondii.
Portes JA; Azeredo NFB; Siqueira PGT; de Souza TG; Fernandes C; Horn A; Candela DRS; de Souza W; DaMatta RA; Seabra SH
Parasitol Res; 2018 Sep; 117(9):2795-2805. PubMed ID: 29934691
[TBL] [Abstract][Full Text] [Related]
10. Toxoplasma gondii in South America: a differentiated pattern of spread, population structure and clinical manifestations.
de Lima Bessa G; de Almeida Vitor RW; Dos Santos Martins-Duarte E
Parasitol Res; 2021 Sep; 120(9):3065-3076. PubMed ID: 34390383
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Efficacy of Drugs against Toxoplasma gondii Combined with Immunomodulators.
Köksal ZŞ; Yanik K; Bilgin K; Yılmaz EM; Hokelek M
Jpn J Infect Dis; 2016; 69(2):113-7. PubMed ID: 26166498
[TBL] [Abstract][Full Text] [Related]
12. Discovery of Potent and Selective Halogen-Substituted Imidazole-Thiosemicarbazides for Inhibition of
Paneth A; Węglińska L; Bekier A; Stefaniszyn E; Wujec M; Trotsko N; Hawrył A; Hawrył M; Dzitko K
Molecules; 2019 Apr; 24(8):. PubMed ID: 31022878
[TBL] [Abstract][Full Text] [Related]
13. Licochalcone A: An effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo.
Si H; Xu C; Zhang J; Zhang X; Li B; Zhou X; Zhang J
Int J Parasitol Drugs Drug Resist; 2018 Aug; 8(2):238-245. PubMed ID: 29684680
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of antiretroviral compounds against Toxoplasma gondii in vitro.
Wang JL; Elsheikha HM; Li TT; He JJ; Bai MJ; Liang QL; Zhu XQ; Cong W
Int J Antimicrob Agents; 2019 Dec; 54(6):814-819. PubMed ID: 31479744
[TBL] [Abstract][Full Text] [Related]
15. Purinergic Signaling: A Common Path in the Macrophage Response against
Petit-Jentreau L; Tailleux L; Coombes JL
Front Cell Infect Microbiol; 2017; 7():347. PubMed ID: 28824882
[TBL] [Abstract][Full Text] [Related]
16. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
Tomioka H
Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
[TBL] [Abstract][Full Text] [Related]
17. In vitro biological activity of extracts from marine bacteria cultures against Toxoplasma gondii and Mycobacterium tuberculosis.
Quintero M; Blandón LM; Vidal OM; Guzman JD; Gómez-Marín JE; Patiño AD; Molina DA; Puerto-Castro GM; Gómez-León J
J Appl Microbiol; 2022 Apr; 132(4):2705-2720. PubMed ID: 34856041
[TBL] [Abstract][Full Text] [Related]
18. Pravastatin and Simvastatin Pretreatment in Combination with Pyrimethamine and Sulfadiazine Reduces Infection Process of Toxoplasma gondii Tachyzoites (RH Strain) in HeLa Cells.
Sanfelice RADS; da Silva SS; Bosqui LR; Machado LF; Miranda-Sapla MM; Panagio LA; Navarro IT; Conchon-Costa I; Pavanelli WR; Almeida RS; Costa IN
Acta Parasitol; 2019 Sep; 64(3):612-616. PubMed ID: 31286354
[TBL] [Abstract][Full Text] [Related]
19. Lectins from
; Ramos EL; Santana SS; Silva MV; Santiago FM; Mineo TW; Mineo JR
Front Cell Infect Microbiol; 2016; 6():164. PubMed ID: 27933277
[TBL] [Abstract][Full Text] [Related]
20. Tylvalosin demonstrates anti-parasitic activity and protects mice from acute toxoplasmosis.
Yuan W; Jia H; Tang X; Xin T; Liu X; Wang Z; Li X; Zhao Z; Liu L; Liang L; Zhao X; Zhao Z
Life Sci; 2022 Apr; 294():120373. PubMed ID: 35123999
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
